Eosinophilic myeloid disorders: New classification and novel therapeutic strategies

Current Opinion in Hematology

Volumn 17, Issue 2, 2010, Pages 117-124

  Gotlib, Jason ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic eosinophilic leukemia; FIP1L1 PDGFRA; Idiopathic hypereosinophilic syndrome; Imatinib; PDGFRB

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CD52 ANTIGEN; DASATINIB; IMATINIB; INTERLEUKIN 5; MEPOLIZUMAB; MIDOSTAURIN; PREDNISONE; RESLIZUMAB; SORAFENIB;

ALGORITHM; CHRONIC EOSINOPHILIC LEUKEMIA; DISEASE CLASSIFICATION; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FGFR1 GENE; FIP1L1 GENE; GENE; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; PATHOPHYSIOLOGY; PDGFRA GENE; PDGFRB GENE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA, MYELOID; PROTEIN KINASE INHIBITORS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 76749141364     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283366c70     Document Type: Review

References (59)

1. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968; 68:1220-1229.
2. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine 1975; 54:1-27.
3. Bain B, Pierre R, Imbert M, et al. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. pp. 29-31.
4. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRa fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103:2879-2891.
5. Bain BJ, Gilliland DG, Horny H-P, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp. 68-73.
6. Bain BJ, Gilliland DG, Horny H-P, Vardiman JW. Chronic eosinophilic leu-kaemia, not otherwise specified. In: Swerdlow S, Harris NL, Stein H, Jaffe ES, Theile J, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. pp. 51-53.
7. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307-316.
8. Forrest DL, Horsman DE, Jensen CL, et al. Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosome abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998; 107:65-68.
9. Roufosse F, Cogan R, Goldman M.The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54:169-184.
10. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660-4666.
11. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093-3096.
12. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201-1214.
13. Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100:7830-7835.
14. Gotlib J, Cools J. Five years since the discovery of the FIPL1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22:1999-2010.
15. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat Genet 1998; 18:84-87.
16. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood 1998; 92:1735-1742.
17. Popovici C, Adelaide J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci USA 1998; 95:5712-5717.
18. Smedley D, Hamoudi R, Clark J, et al. The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP. Hum Mol Genet 1998; 7:637-642.
19. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038-3045.
20. Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007; 120:680-687.
21. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007; 21:1183-1188.
22. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001; 3:9.
23. Gleich GJ, Leiferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002; 359:1577-1578.
24. Ault P, Cortes J, Koller C, et al. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. LeukRes 2002; 26:881-884.
25. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473-478.
26. Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007; 92:1173-1179.
27. Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109:4635-4640.
28. Klion AD, Robyn J, Maric I, et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007; 110:3552-3556.
29. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006; 30:965-970.
30. Helbig G, Stella-Hołowiecka B, Majewski M, et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008; 141:200-204.
31. Cross DM, Cross NC, Burgstaller S, et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109:61-64.
32. Chen J, DeAngelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 2004; 101:14479-14484.
33. Pardanani A, Reeder T, Porrata L, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003; 101:3391-3397.
34. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456-3457.
35. von Bubnoff N, Sandherr M, Schlimok G, et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFRalpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2004; 19:286-287.
36. Ohnishi H, Kandabashi K, Maeda Y, et al. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006; 134:547-549.
37. Lierman E, Michaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009; 23:845-851.
38. Simon D, Salemi S, Yousefi S, Simon HU. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008; 121:1054-1056.
39. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108:2332-2338.
40. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloprolifera-tive disease. Cancer Cell 2003; 3:459-469.
41. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006; 108:1374-1376.
42. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005; 106:3206-3213.
43. von Bubnoff N, Gorantla SP, Thone S, et al. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006; 107:4970-4971.
44. Quiquandon I, Claisse JF, Capiod JC, et al. Alpha-interferon and hypereosi-nophilic syndrome with trisomy 8: karyotypic remission. Blood 1995; 85:2284-2285.
45. Luciano L, Catalano L, Sarrantonio C, et al. aIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haema-tologica 1999; 84:651-653.
46. Yamada O, Kitahara K, Imamura K, et al. Clinical and cytogenetic remission induced by interferon-a in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 1998; 58:137-141.
47. Malbrain ML, Van den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematologi-cal and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol 1996; 92:176-183.
48. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hyper-eosinophilic syndrome to interferon alpha. J Allergy Clin Immunol 1994; 94:1318-1326.
49. Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hyper-eosinophilic syndrome: consideration of five cases. Ann Hematol 1998; 77:161-164.
50. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol 2000; 27:110-115.
51. HartTK, CookRM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB\-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001; 108:250-257.
52. Plotz SG, Simon HU, Darsow U, et al. Use of an antiinterleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349:2334-2339.
53. Garrett JK, Jameson SC, Thomson B, et al. Antiinterleukin-5 (mepolizumab) therapy for hypereosinophilic syndrome. J Allergy Clin Immunol 2004; 113:115-119.
54. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal antiinterleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 2004; 103:2939-2941.
55. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358:1215-1228.
56. Yamada Y, Rothenberg ME, Lee AW, et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006; 107:4071-4079.
57. Pitini V, Teti D, Arrigo C, Righi M, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T-cells: a case report. Br J Haematol 2004; 127:477.
58. Sefcick A, Sowter D, DasGupta E, et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004; 124:558-559.
59. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hyper-eosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009; 15:368-373.